Special dividend: Is now the time to buy NIB shares for income?

NIB shares now offer a yield well over 4%.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are quite a few S&P/ASX 200 Index (ASX: XJO) shares that are reporting their latest earnings to investors this Monday. ASX health insurance stock NIB Holdings Ltd (ASX: NHF) is one of them. Unfortunately, investors did not like what they saw, with NIB shares currently down a nasty 10% to $6.66 each.

However, this represents a compelling buying opportunity for income investors.

Before we get into why, let's go over what NIB had to say this morning.

As my Fool colleague covered earlier today, it was an interesting earnings report to go through. NIB reported group revenues of $3.8 billion for its 2026 financial year, up 6.2% on what the company brought in over FY 2025. Group underlying profits were up 9.1% to $260.9 million, but statutory net profits after tax fell 5.9% to $186.9 million.

It seems investors did not like what they saw, going off the steep drop in NIB shares that we are currently witnessing.

But let's talk about income. NIB has always been a decent dividend stock. The company has substantially increased its income in recent years, going from paying out an annual 14 cents per share in fully franked dividends in 2020 to 29 cents per share in 2025.

2025's payouts consisted of an April interim dividend of 13 cents per share and an October final dividend of 16 cents per share. Both payments came fully franked, as is NIB's habit. The company's first dividend of 2026 matched that of the 2025 interim dividend, with shareholders once again bagging 13 cents per share.

Two lab workers fist pump each other.

Image source: Getty Images

NIB shares drop despite new special dividend

Today, though, NIB threw some spice into the income soup. It declared a final dividend of 16 cents per share, once again matching 2025's ordinary payout. But it also unveiled a special dividend alongside its ordinary payout. Yep, shareholders are set to enjoy a concurrent dividend worth another 5 cents per share. That will bring NIB's dividend total for 2026 to 34 cents per share.

Right now, NIB shares are trading on a trailing dividend yield of 4.36% (boosted mightily by today's steep share price sell-off). However, we can now assign the stock a forward yield of 5.12%.

So does that make NIB a buy for income? Well, investors shouldn't take too much from this special dividend. It is entirely possible, even likely, that 2027's total payouts don't match what investors will receive in 2026. Special dividends by nature tend to be one-off events.

Saying that, this company occupies a defensive sector of the ASX and has a strong history of delivering dividend increases. As such, I would be happy to include it in a diversified income-focused portfolio.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why are Telix Pharmaceuticals shares charging higher today?

A key approval is good news for this drug developer.

Read more »

A man holding a cup of coffee puts his thumb up and smiles with a laptop open.
Healthcare Shares

Telix Pharmaceuticals shares: FDA approves Pixclara brain cancer drug

Telix Pharmaceuticals’ US FDA approval for Pixclara is a first for glioma imaging, expanding its precision medicine offerings.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

CSL shares just fell 5% after a strong rally. Is the recovery losing steam?

Can CSL’s improving outlook justify its higher share price?

Read more »

ASX share investor sitting with a laptop on a desk, pondering something.
Healthcare Shares

Higher or lower: Where are CSL shares going next?

The biotech giant has been on a tear. Is it too late to invest? Let's find out.

Read more »

Doctor with stethoscope holding a tablet and smiling.
Healthcare Shares

ASX healthcare shares are 39% higher since June. Are you missing out?

Healthcare stocks endured a long slump before the sector pivoted three months ago.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

EchoIQ shares just crashed 48%. What happens now?

One regulatory letter, half the market cap.

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

CSL shares are up 90%. How much higher can they go?

CSL’s recovery could deliver more upside or another sharp reversal.

Read more »

A woman's hair is blown back and her face is in shock at this big news.
Healthcare Shares

Why has this ASX biotech fallen nearly 50% today?

A knockback for a key approval has rocked this company.

Read more »